login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Pulsar Stent shows positive outcomes in 4EVER clinical study


Wednesday, 23 May 2012 12:34
Pulsar
Pulsar

The six-month results from the prospective, multicentre, single-arm 4EVER study (Trial investigating the safety of 4F endovascular treatment of infra-inguinal arterial stenotic disease) demonstrate efficacy and safety of the Pulsar Stent System (Biotronik) in 120 superficial femoral arterypatients.


Analysis of the 120 patients showed excellent device performance, very promising patency rates and convincing evidence of the benefits of lower limb intervention on a 4F platform. Although only the interim results were presented at the Leipzig Interventional Course (LINC 2012) in Leipzig, Germany, Biotronik announced that analysis of the full cohort has recently been made available.

The 4EVER study was initiated by Marc Bosiers, Dendermonde, Belgium, to investigate the efficacy of Pulsar stents and also the feasibility of treating patients with Biotronik’s 4F devices namely the Fortress 4F sheath, together with the Astron Pulsar and Pulsar-18 SE stents.

In total, 120 patients were recruited into the study. Six-month primary patency is documented as being as high as 90.0%. Average lesion length in the Pulsar-18 subgroup was 10.5cm. On the 4F intervention side, Bosiers presented a complication rate of only 3.3% and a mean manual compression time of around 8 minutes, halving the time experienced when using 6F.


Technical success of 100% clearly supports the possibility for minimally invasive peripheral intervention of the lower limb. When asked during the Biotronik symposium at LINC 2012 whether all patients can be treated with 4F, Koen Deloose, Dendermonde, Belgium, responded, “4F is sufficient for the majority of endovascular treatments.”

Pulsar-18 stents provide an innovative design of ultrathin nitinol struts coated with Probio, a silicone carbide layer that improves the stent’s haemocompatibility and biocompatibility, which is believed to contribute to its positive clinical results. Pulsar-18 is available in diameters of 4–7mm and 20–200mm lengths deliverable through a 4F sheath.


The primary endpoint data, primary patency at twelve months, is expected to be presented at CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 15–19 September 2012 in Lisbon, Portugal.




Add New Comment

Related Items


Most popular


First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Bioresorbable scaffolds can produce comparable acute results to metal stents
Tuesday, 04 Nov 2014
Speaking at the Asian Society for Vascular Surgery meeting (5–7 September, Hong Kong, China), Andrew Holden commented that studies indicate that bioresorbable scaffolds can produce comparable acute ... Bioresorbable scaffolds can produce comparable acute results to metal stents

Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years
Wednesday, 19 Nov 2014
Three-year follow-up results of patients treated with the Supera stent show that nominal deployment or slight compression of the device delivers the best outcomes in terms of durability, and that ... Live from VEITH 2014: SUPERB results show 94% freedom from reintervention with nominal deployment of Supera at three years

Features


A new classification system for acute type B aortic dissection predicting reverse aortic remodelling
Wednesday, 19 Nov 2014
In recent years, primary stent grafting for complicated type B aortic dissection has been applied with favourable results. Thoracic aortic endovascular repair can be offered with a relatively low ... A new classification system for acute type B aortic dissection predicting reverse aortic remodelling

Resolving differences between carotid stenosis management guidelines
Wednesday, 19 Nov 2014
Anne Abbott, Melbroune, Australia, writes that while some variability in guideline recommendations is due to different publication dates, much is due to bias in what evidence is considered and how it ... Resolving differences between carotid stenosis management guidelines

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions